Cosmin P.
- Country
- Romania
- Department
- N/A
Research Overview
- Evaluation of the Efficacy and Safety of Semaglutide with Reduced-Dose Insulin Glargine Versus Titrated Insulin Glargine in Type 2 Diabetes with Overweight
- Efficacy and Safety Comparison of Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 with Insulin Aspart in Adults with Type 1 Diabetes
Data & Insights
Has run more than one trial at 5 of 98 partner sites.
Specializations
Type 2 Diabetes and Overweight
Cosmin Pena is involved in clinical research focused on type 2 diabetes in people with overweight, with attention to glycaemic control and the use of basal insulin in combination with GLP-1 receptor agonist therapy. This area reflects interest in treatment strategies that support improved HbA1c outcomes while addressing insulin-based management in adults with excess body weight.
- HbA1c improvement in type 2 diabetes
- Basal insulin optimization
- Semaglutide in metabolic care
- Overweight-associated diabetes management
His work in this field is linked to outpatient diabetes care at Diabs&Nutricare S.R.L. in Bucharest, with a therapeutic emphasis on metabolic disease management.
Type 1 Diabetes and Insulin Therapy
He is also engaged in research on type 1 diabetes, with a focus on modern insulin therapy approaches that combine once-weekly insulin with mealtime insulin support. The clinical interest in this area centers on improving long-term glycaemic control and simplifying insulin-based treatment for adults living with insulin-dependent diabetes.
- Once-weekly insulin regimens
- Insulin aspart combination therapy
- Insulin glargine comparator care
- Type 1 diabetes glucose management
This research domain highlights his involvement in therapeutic strategies aimed at refining insulin delivery within routine diabetes practice.
Metabolic Endpoints and Glycaemic Outcomes
His clinical trial activity includes a strong focus on measurable metabolic endpoints, particularly changes in HbA1c as a marker of diabetes control. The research landscape covers comparative evaluation of diabetes treatments designed to support stable blood glucose management across both type 1 and type 2 diabetes.
- HbA1c as a therapeutic endpoint
- Blood glucose regulation
- Diabetes treatment comparison
- Insulin-based metabolic control
This area connects his work to practical diabetes innovation through therapies that target clinically relevant metabolic improvement.
Endocrinology and Diabetes Care
Cosmin Pena’s research profile is rooted in endocrinology with a clear concentration on diabetes care. His trial involvement spans both insulin intensification and newer therapeutic combinations, reflecting interest in treatment options for chronic metabolic disease within specialist clinical practice.
- Endocrine disease management
- Diabetes care pathways
- Insulin-based treatment strategies
- Metabolic disease intervention
His activity in this domain is centered on advancing clinically relevant therapeutic options for patients requiring ongoing endocrine follow-up.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.